View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

Notice Summary

United Kingdom-Aldgate: Dose Banded and Patient Specific Doses of Systemic Anti-Cancer Treatments
205365-2019
Barts Health NHS Trust
03 May 2019
07 June 2019
Contract Notice - Open Procedure
No

Notice Abstract

The Trust is the cancer centre for North East London and provides a medical and haematological oncology service including bone marrow transplantation. The chemotherapy pharmacy department has a licensed chemotherapy production unit, providing over 45 000 doses of systemic anti-cancer treatments (SACT) per year.Demand for the provision of SACT has been rising consistently year on year. As such the department has developed a strategy to meet this demand and ensure that patient treatment requirements can be met. This strategy includes maximising efficiency of our existing production capacity by outsourcing doses that can be manufactured externally, to quality standards and that will be safe for the patient.The outsourced doses will be purchased in the form of both ready made dose banded products and patient specific doses.

Notice Details

Contract notice

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting Change entity

I.1) Name and addresses

Barts Health NHS Trust

2nd Floor, 9 Prescot Street

Aldgate

E1 8PR

UK

Contact person: Mr Fabien Affonso

Telephone: +44 20737770004103

E-mail: Fabien.Affonso@nhs.net

NUTS: UK

Internet address(es)

Main address: http://www.bartshealth.nhs.uk

Address of the buyer profile: http://www.bartshealth.nhs.uk

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge at:

https://procontract.due-north.com/Login


Additional information can be obtained from the abovementioned address


Tenders or requests to participate must be sent electronically to:

https://procontract.due-north.com/Login


I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Dose Banded and Patient Specific Doses of Systemic Anti-Cancer Treatments (SACT)

Reference number: DN406495

II.1.2) Main CPV code

85149000

 

II.1.3) Type of contract

Supplies

II.1.4) Short description

The Trust is the cancer centre for North East London and provides a medical and haematological oncology service including bone marrow transplantation. The chemotherapy pharmacy department has a licensed chemotherapy production unit, providing over 45 000 doses of systemic anti-cancer treatments (SACT) per year.

Demand for the provision of SACT has been rising consistently year on year. As such the department has developed a strategy to meet this demand and ensure that patient treatment requirements can be met. This strategy includes maximising efficiency of our existing production capacity by outsourcing doses that can be manufactured externally, to quality standards and that will be safe for the patient.

The outsourced doses will be purchased in the form of both ready made dose banded products and patient specific doses.

II.1.6) Information about lots

This contract is divided into lots: No

II.2) Description

II.2.3) Place of performance

NUTS code:

UK

II.2.4) Description of the procurement

The following drugs may be required (not exhaustive and subject to change as new drugs are commissioned).

Patient specific doses of systemic anti-cancer treatments:

— bleomycin infusion,

— bleomycin injection,

— bortezomib injection,

— carboplatin infusion,

— cetuximab infusion,

— cisplatin infusion,

— cyclophosphamide infusion,

— cytarabine injection,

— cytarabine infusion,

— daratumumab infusion,

— docetaxel infusion,

— etoposide infusion,

— fluorouracil infusion in bags and LV2, LV5 and LV10 pumps,

— gemcitabine infusion,

— ifosfamide infusion,

— irinotecan infusion,

— methotrexate infusion,

— methotrexate injection,

— oxaliplatin infusion,

— paclitaxel infusion,

— pembrolizumab infusion,

— pemetrexed infusion,

— trastuzumab infusion (both branded and biosimilar),

— vincristine infusion,

— vincristine injection,

— vinorelbine infusion.

Dose banded:

— bleomycin infusion,

— bortezomib injection,

— carboplatin infusion,

— cisplatin infusion,

— cyclophosphamide infusion,

— docetaxel infusion,

— doxorubicin,

— fluorouracil infusion in 100 ml bags,

— fluorouracil infusion in LV5 pumps,

— gemcitabine infusion,

— irinotecan infusion,

— oxaliplatin infusion,

— paclitaxel infusion,

— pembrolizumab infusion,

— pemetrexed infusion,

— trastuzumab infusion (both branded and biosimilar),

— vincristine infusion,

— vinblastine infusion.

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Duration in months: 36

This contract is subject to renewal: Yes

Description of renewals:

2 renewals of 12 months each.

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: No

II.2.12) Information about electronic catalogues

Tenders must be presented in the form of electronic catalogues or include an electronic catalogue

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section III: Legal, economic, financial and technical information

III.1) Conditions for participation

III.1.2) Economic and financial standing

Selection criteria as stated in the procurement documents


III.1.3) Technical and professional ability

Selection criteria as stated in the procurement documents


III.2) Conditions related to the contract

III.2.2) Contract performance conditions

The following are required and the list is not exhaustive and subject to development and agreement with the successful bidder(s):

(i) complaint handling;

(ii) delivery (dose banded) — maximum 1 week from order placement compliant with principles of good distribution practice (GDP). Delivery times will be required Mon-Fri 9:00 a.m.-5:00 p.m. and Sat 9:00 a.m.-12:00 p.m. and supplied to the chemotherapy pharmacy on 7th Floor, KGV building at St. Bartholomew’s Hospital;

(iii) delivery (dose specific) — delivery options including next day, 24 and 48 hour delivery compliant with principles of good distribution practice (GDP). Delivery times will be required Mon-Fri 9:00 a.m.-5:00 p.m. and Sat 9:00 a.m.-12:00 p.m. and supplied to the chemotherapy pharmacy on 7th Floor, KGV building at St. Bartholomew’s Hospital;

(iv) contacts — a point of contact should be available via telephone and email, Mon-Fri, 9:00 a.m.-5:00 p.m.

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 07/06/2019

Local time: 12:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

IV.2.7) Conditions for opening of tenders

Date: 07/06/2019

Local time: 12:00

Section VI: Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.4) Procedures for review

VI.4.1) Review body

Barts Health NHS Trust

London

UK

VI.5) Date of dispatch of this notice

29/04/2019